📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-26 15:55
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Prism Medico Seeks Approval to Divert ₹23 Cr Preferential Issue Proceeds to Related Party IWPL
Prism Medico and Pharmacy has issued its 24th AGM notice proposing a major variation in the utilisation of its ₹25.00 Cr preferential issue proceeds. The company plans to cancel its original ₹23.00 Cr manufacturing capex (₹15.69 Cr for plant & machinery and ₹7.31 Cr for civil work) and reallocate the entire ₹23.00 Cr to acquire 2,30,00,000 equity shares in related-party entity Infuze Well Private Limited (IWPL). The proposed ₹23.00 Cr transaction exceeds the company's total market capitalisation of ₹18 Cr and represents a significant capital reallocation to a related party.
Confidence: HIGH
What changedThe company dropped its plan to build manufacturing facilities directly and is instead deploying ₹23.00 Cr into related-party entity Infuze Well Private Limited to make it a subsidiary.
Why it mattersThe reallocation amounts to ~128% of the company's market capitalisation (₹18 Cr), materially shifting corporate focus and raising related-party exposure risks.
Revised investment in IWPL: Rs. 23,00,00,000Investment vs Market Cap: ~128%Original capex discontinued: Rs. 23,00,00,000Total preferential issue proceeds: Rs. 25,00,00,000AGM date: 19th day of September 2026
📅 Short termMarket attention will focus on shareholder approval for the material related-party transaction and warrant exercise timelines at the September 19, 2026 AGM.
📈 Long termAborting direct asset creation to invest heavily in a related entity fundamentally alters business execution risk and governance dynamics.
⚠ Risk flags
- Material related-party transaction of ₹23 Cr exceeding current market cap
- Cancellation of core manufacturing capex
- Proceed deployment contingent upon future warrant conversion payments
Key Highlights
Proposes reallocating ₹23.00 Cr of issue proceeds from manufacturing capex to subscribe to equity shares of related party Infuze Well Pvt Ltd.
Discontinues original capex plans of ₹15.69 Cr for plant & machinery and ₹7.31 Cr for civil structures.
Prefunded preferential issue comprised 75,00,000 equity shares and 50,00,000 convertible warrants totalling ₹25.00 Cr.
Plans to acquire 2,30,00,000 equity shares of IWPL at ₹10 per share to make it a subsidiary.
Shareholder voting scheduled at the 24th AGM on September 19, 2026.
👀 What to Watch
Track the voting outcome of the special resolutions at the AGM on September 19, 2026, and scrutinise disclosures on the business viability, assets, and financials of Infuze Well Private Limited.
Prism Medico Seeks Approval to Divert ₹23 Cr Issue Proceeds to Related Party Infuze Well
Prism Medico and Pharmacy has issued its 24th AGM notice seeking shareholder approval to modify the objects of its ₹25.00 crore preferential issue (75 lakh shares and 50 lakh convertible warrants). The company has discontinued its original manufacturing capex plans of ₹15.69 crore for plant & machinery and ₹7.31 crore for civil works. Instead, it proposes to allocate ₹23.00 crore towards a strategic investment in freshly issued shares of related party Infuze Well Private Limited (IWPL) to make it a subsidiary.
Confidence: HIGH
What changedPrism Medico canceled its direct manufacturing plant and civil capex plans and proposed redirecting ₹23.00 crore of preferential issue proceeds to subscribe to shares of related party Infuze Well Private Limited.
Why it mattersThe ₹23.00 crore reallocation exceeds the company's entire market capitalization of ₹18 crore, marking a massive strategic shift toward an unlisted related-party entity rather than building in-house manufacturing capacity.
Total Preferential Issue Size: Rs. 25,00,00,000Reallocated Amount to Related Party: Rs. 23,00,00,000Reallocation vs Market Cap: ~128%Amount Utilised Till Date (Land & Building): Rs. 1,00,00,000AGM Date: September 19, 2026
📅 Short termShareholder voting and scrutiny around the related-party transaction and variation of objects will be the primary focus heading into the September 19 AGM.
📈 Long termShifting funds into a related party subsidiary fundamentally alters the company's operating profile and capital allocation risks compared to owning physical manufacturing assets.
⚠ Risk flags
- Related-party transaction: ₹23 crore diverted to an affiliated entity.
- Capital reallocation risk: complete cancellation of previously approved manufacturing capex.
- Contingent funding: deployment is dependent on full realization of warrant exercise consideration.
Key Highlights
Discontinued ₹23.00 crore original capex allocated for manufacturing plant, machinery (₹15.69 Cr), and civil structures (₹7.31 Cr).
Reallocated ₹23.00 crore towards acquiring equity shares in related party Infuze Well Private Limited (IWPL) to make it a subsidiary.
Total preferential issue size stands at ₹25.00 crore, consisting of 75,00,000 equity shares and 50,00,000 convertible warrants allotted on May 05, 2026.
₹1.00 crore has been utilized till date towards purchase of land and building in District Sirmaur, Himachal Pradesh.
24th AGM scheduled for September 19, 2026 via video conferencing to seek shareholder approval.
👀 What to Watch
Track the voting outcome of the Special Resolution at the AGM on September 19, 2026, and watch for further disclosures regarding Infuze Well Private Limited's valuation, financials, and business model.
Prism Medico proposes diverting ₹23 Cr preferential issue proceeds to acquire related party IWPL
Prism Medico and Pharmacy Ltd has proposed to vary the objects of its ₹25.00 Cr preferential issue (75,00,000 equity shares and 50,00,000 convertible warrants). The company is discontinuing previously planned capex of ₹15.69 Cr for medicine manufacturing machinery and ₹7.31 Cr for civil structures. Instead, ₹23.00 Cr will be redirected as a strategic investment to acquire freshly issued shares in related party Infuze Well Private Limited (IWPL) to make it a subsidiary, subject to shareholder approval at the AGM on September 19, 2026.
Confidence: HIGH
What changedThe company cancelled its ₹23 Cr direct manufacturing capex plans to redirect the funds into acquiring control of a related party entity, Infuze Well Private Limited.
Why it mattersThe ₹23 Cr reallocation exceeds the company's entire market capitalization (₹18 Cr) and net worth (₹13 Cr), fundamentally altering its asset base and risk profile through a related-party transaction.
Total Preferential Issue Size: ₹25,00,00,000Revised Allocation to IWPL: ₹23,00,00,000Discontinued Capex Allocation: ₹23,00,00,000Reallocated Amount vs Market Cap: ~128%AGM Date: 19th September 2026
📅 Short termShareholders will vote on the variation of objects at the upcoming AGM on September 19, 2026.
📈 Long termPivoting away from organic manufacturing infrastructure toward a related-party acquisition significantly shifts operational reliance and corporate governance dynamics.
⚠ Risk flags
- Substantial related-party transaction (₹23 Cr)
- Cancellation of direct manufacturing expansion plans
- Dependency on full receipt of warrant exercise proceeds
Key Highlights
Diverting ₹23.00 Cr of preferential issue proceeds to acquire shares in related party Infuze Well Pvt Ltd
Discontinued ₹15.69 Cr allocation for plant and machinery and ₹7.31 Cr for civil structures
Preferential issue comprises 75,00,000 equity shares and 50,00,000 convertible warrants totaling ₹25.00 Cr
Deployment of ₹23.00 Cr is contingent upon receipt of balance warrant exercise consideration
24th AGM scheduled for September 19, 2026 via video conferencing to seek special resolution approval
👀 What to Watch
Track the outcome of the special resolution at the AGM on September 19, 2026, and look for valuation and business disclosures regarding related entity Infuze Well Private Limited.
Prism Medico to Divert ₹23 Cr Preferential Funds into Related-Party Firm Infuze Well
Prism Medico has issued an AGM notice seeking shareholder approval to modify the objects of its ₹25.00 crore preferential issue. The company is discontinuing its planned ₹23.00 crore direct capex (machinery and civil works) to instead invest ₹23.00 crore into freshly issued equity shares of related-party entity Infuze Well Private Limited (IWPL) to make it a subsidiary. Whole-Time Director Sakshi Laller holds a 19.40% stake in IWPL. Additionally, the company is seeking approval for up to ₹70.00 crore of related-party transactions in FY27 against FY26 revenue of just ₹2.47 crore.
Confidence: HIGH
What changedPrism Medico is scrapping its internal ₹23 Cr pharma manufacturing capex plan to instead acquire a controlling stake in related-party Infuze Well Private Limited.
Why it mattersThe ₹23 Cr redeployment is larger than the company's current market cap (₹18 Cr) and net worth (₹13 Cr), materially shifting the business profile and raising significant related-party governance considerations.
Preferential Issue Reallocation: ₹23,00,00,000Reallocated Amount vs Market Cap: ~128%FY26 Consolidated Turnover: ₹246.95 lakhsProposed FY27 RPT Limit: ₹70 croresDirector Sakshi Laller's Stake in Target (IWPL): 19.40%
📅 Short termVoting scrutiny at the AGM on September 19, 2026, as related parties are barred from voting on the material RPT resolution.
📈 Long termIntegration and commercial viability of Infuze Well Private Limited will determine whether the ₹23 Cr capital reallocation yields adequate return on equity.
⚠ Risk flags
- Related-party transaction risk: Diverting issue proceeds to a company where a promoter-director holds 19.40% equity.
- Execution/Strategy shift: Complete cancellation of original direct manufacturing plant & machinery setup.
Key Highlights
Diverting ₹23.00 crore from originally planned manufacturing capex into acquiring related-party Infuze Well Private Limited.
Original capex objects of ₹15.69 crore for plant/machinery and ₹7.31 crore for civil works discontinued entirely.
Proposed investment of ₹23.00 crore exceeds the company's entire market capitalization of ~₹18 crore.
Seeking shareholder approval for up to ₹70.00 crore in related-party purchase/sale transactions for FY27.
24th AGM scheduled for September 19, 2026, via Video Conferencing.
👀 What to Watch
Track shareholder voting results at the September 19, 2026 AGM, specifically whether minority shareholders approve the variation of preferential issue objects and material related-party transactions.
Prism Medico Reports Zero Operating Revenue in Q1 FY27; Net Loss of Rs 5.83 Lakh
Prism Medico and Pharmacy Ltd reported a significant downturn in Q1 FY27, with revenue from operations falling to zero from Rs 158.87 Lakhs in the same quarter last year. The company posted a net loss of Rs 5.83 Lakhs, as other income of Rs 9.06 Lakhs failed to cover total expenses of Rs 14.89 Lakhs. Notably, the paid-up equity share capital more than doubled to Rs 13.56 Cr from Rs 6.06 Cr in the previous quarter, indicating a major capital infusion or corporate action not fully detailed in the results.
Confidence: HIGH
What changedThe company's core business operations generated no revenue during the quarter, and the equity capital base was expanded by over 120%.
Why it mattersFor a micro-cap NBFC, the lack of operating income is a critical risk to business viability, suggesting the company is currently surviving solely on non-core income.
Revenue from Operations (Q1): Rs 0.00Net Loss (Q1): Rs 5.83 LakhsOther Income: Rs 9.06 LakhsCurrent Equity Capital: Rs 1,356.34 LakhsPrevious Equity Capital: Rs 606.34 LakhsCapital Increase vs Market Cap: ~46%
📅 Short termNegative sentiment is expected as the market reacts to the loss and the disappearance of operating revenue.
📈 Long termHigh risk; the company's structural significance depends on its ability to restart operations and effectively utilize its expanded capital base.
⚠ Risk flags
- Zero operating revenue
- Net loss
- Significant equity dilution
- High dependence on other income
Key Highlights
Revenue from operations dropped to Rs 0.00 in Q1 FY27 compared to Rs 158.87 Lakhs in Q1 FY26.
Net Loss of Rs 5.83 Lakhs recorded for the quarter ended June 30, 2026.
Paid-up equity share capital increased by 123% to Rs 1,356.34 Lakhs from Rs 606.34 Lakhs.
Other expenses of Rs 13.02 Lakhs constituted the bulk of the quarter's costs.
Total comprehensive income swung from a profit of Rs 65.73 Lakhs YoY to a loss of Rs 5.83 Lakhs.
👀 What to Watch
Investors should monitor management's explanation for the total cessation of operating revenue and track the deployment of the newly raised capital (Rs 7.5 Cr increase in equity base).
